Placebo-controlled evidence across 9013 patients showed a lower composite risk (HR 0.85) driven by reduced worsening HF events rather than any detectable mortality benefit. Worsening HF events were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results